82 related articles for article (PubMed ID: 8747407)
1. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
[TBL] [Abstract][Full Text] [Related]
2. Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population.
Payan M; Rouini MR; Tajik N; Ghahremani MH; Tahvilian R
Daru; 2014 Dec; 22(1):81. PubMed ID: 25498969
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.
Goldstein JA
Br J Clin Pharmacol; 2001 Oct; 52(4):349-55. PubMed ID: 11678778
[TBL] [Abstract][Full Text] [Related]
4. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population.
Roh HK; Dahl ML; Tybring G; Yamada H; Cha YN; Bertilsson L
Pharmacogenetics; 1996 Dec; 6(6):547-51. PubMed ID: 9014204
[TBL] [Abstract][Full Text] [Related]
5. CYP2C19 gene polymorphism in Ningxia.
Yang Z; Xie Y; Zhang D; Zou Y; Li X; Chen R; Zhang X; Chen S; Bai F
Pharmacol Rep; 2023 Jun; 75(3):705-714. PubMed ID: 36913175
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans.
Elbe A; Foerster KI; Blank A; Rose P; Burhenne J; Haefeli WE; Mikus G
Eur J Clin Pharmacol; 2022 Jun; 78(6):975-987. PubMed ID: 35238961
[TBL] [Abstract][Full Text] [Related]
7. Influence of
Morino Y; Sugimoto M; Nagata N; Niikiura R; Iwata E; Hamada M; Kawai Y; Fujimiya T; Takeuchi H; Unezaki S; Kawai T
Front Pharmacol; 2021; 12():759249. PubMed ID: 34721043
[No Abstract] [Full Text] [Related]
8. Genetic Polymorphism of CYP2C9 Among Sistani Ethnic Group in Gorgan.
Marjani A; Gharanjik AM
Indian J Clin Biochem; 2018 Apr; 33(2):208-213. PubMed ID: 29651213
[TBL] [Abstract][Full Text] [Related]
9. Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients.
Zhuo ZL; Xian HP; Long Y; Liu C; Sun YY; Ma YT; Gao H; Zhao JZ; Zhao XT
Anatol J Cardiol; 2018 Feb; 19(2):123-129. PubMed ID: 29350207
[TBL] [Abstract][Full Text] [Related]
10. Analysis of CYP2C19 Genetic Polymorphism in a Large Ethnic Hakka Population in Southern China.
Zhong Z; Hou J; Li B; Zhang Q; Liu S; Li C; Liu Z; Yang M; Zhong W; Zhao P
Med Sci Monit; 2017 Dec; 23():6186-6192. PubMed ID: 29288619
[TBL] [Abstract][Full Text] [Related]
11. Genotype‑phenotype analysis of CYP2C19 in the Tibetan population and its potential clinical implications in drug therapy.
Jin T; Zhang X; Geng T; Shi X; Wang L; Yuan D; Kang L
Mol Med Rep; 2016 Mar; 13(3):2117-23. PubMed ID: 26781306
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms and phenotypic analysis of drug-metabolizing enzyme CYP2C19 in a Li Chinese population.
Ding Y; Xu D; Zhang X; Yang H; Geng T; He P; Yao J; Yi S; Xu H; Wu D; Wang X; Jin T
Int J Clin Exp Pathol; 2015; 8(10):13201-8. PubMed ID: 26722519
[TBL] [Abstract][Full Text] [Related]
13. Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway.
Feng S; Cleary Y; Parrott N; Hu P; Weber C; Wang Y; Yin OQ; Shi J
Eur J Clin Pharmacol; 2015 May; 71(5):617-24. PubMed ID: 25801493
[TBL] [Abstract][Full Text] [Related]
14. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.
Chang M; Tybring G; Dahl ML; Lindh JD
Clin Pharmacokinet; 2014 Sep; 53(9):801-11. PubMed ID: 25154506
[TBL] [Abstract][Full Text] [Related]
15. Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese.
Sugimoto M; Shirai N; Nishino M; Kodaira C; Uotani T; Sahara S; Ichikawa H; Kagami T; Sugimoto K; Furuta T
Eur J Clin Pharmacol; 2014 Sep; 70(9):1073-8. PubMed ID: 24996380
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.
Sugimoto M; Furuta T
World J Gastroenterol; 2014 Jun; 20(21):6400-11. PubMed ID: 24914361
[TBL] [Abstract][Full Text] [Related]
17. Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians.
Kohlrausch FB; Carracedo Á; Hutz MH
Mol Biol Rep; 2014 Mar; 41(3):1453-60. PubMed ID: 24443221
[TBL] [Abstract][Full Text] [Related]
18. Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.
Nordmark A; Andersson A; Baranczewski P; Wanag E; Ståhle L
Eur J Clin Pharmacol; 2014 Feb; 70(2):167-78. PubMed ID: 24186263
[TBL] [Abstract][Full Text] [Related]
19. A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers.
Pedersen RS; Damkier P; Christensen MM; Brosen K
Eur J Clin Pharmacol; 2013 Dec; 69(12):1997-9. PubMed ID: 23917460
[TBL] [Abstract][Full Text] [Related]
20. Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group.
Tabari RG; Marjani A; Ataby OA; Mansourian AR; Samai NM
Oman Med J; 2013 Jul; 28(4):237-44. PubMed ID: 23904915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
